Therapy of intermediate uveitis

被引:2
|
作者
Doycheva, D. [1 ]
Deuter, C. [1 ]
Zierhut, M. [1 ]
机构
[1] Univ Augenklin Tubingen, D-72076 Tubingen, Germany
来源
OPHTHALMOLOGE | 2014年 / 111卷 / 12期
关键词
Corticosteroids; Immunosuppressive agents; Biologics; Inflammation; Vitreous body; CHRONIC NONINFECTIOUS UVEITIS; INTRAVITREAL BEVACIZUMAB AVASTIN; JUVENILE IDIOPATHIC ARTHRITIS; REFRACTORY MACULAR EDEMA; POSTERIOR UVEITIS; TRIAMCINOLONE ACETONIDE; MYCOPHENOLATE-MOFETIL; CHILDHOOD UVEITIS; CYCLOSPORINE; INFLAMMATION;
D O I
10.1007/s00347-014-3201-2
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Intermediate uveitis is a form of intraocular inflammation in which the vitreous body is the major site of inflammation. Intermediate uveitis is primarily treated medicinally and systemic corticosteroids are the mainstay of therapy. When recurrence of uveitis or side effects occur during corticosteroid therapy an immunosuppressive treatment is required. Cyclosporine A is the only immunosuppressive agent that is approved for therapy of uveitis in Germany; however, other immunosuppressive drugs have also been shown to be effective and well-tolerated in patients with intermediate uveitis. In severe therapy-refractory cases when conventional immunosuppressive therapy has failed, biologics can be used. In patients with unilateral uveitis or when the systemic therapy is contraindicated because of side effects, an intravitreal steroid treatment can be carried out. In certain cases a vitrectomy may be used.
引用
收藏
页码:1219 / 1232
页数:14
相关论文
共 50 条
  • [31] Outcomes of non-infectious Paediatric uveitis in the era of biologic therapy
    Cann, Megan
    Ramanan, Athimalaipet V.
    Crawford, Andrew
    Dick, Andrew D.
    Clarke, Sarah L. N.
    Rashed, Fatima
    Guly, Catherine M.
    PEDIATRIC RHEUMATOLOGY, 2018, 16
  • [32] Uveitis
    Dunn, James P.
    PRIMARY CARE, 2015, 42 (03): : 305 - +
  • [33] Pediatric Uveitis in a Well-Defined Population: Improved Outcomes with Immunosuppressive Therapy
    Curragh, David S.
    O'Neill, Marie
    McAvoy, Clara E.
    Rooney, Madeleine
    McLoone, Eibhlin
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2018, 26 (06) : 978 - 985
  • [34] Review and update of intraocular therapy in noninfectious uveitis
    Sallam, Ahmed
    Taylor, Simon R. J.
    Lightman, Sue
    CURRENT OPINION IN OPHTHALMOLOGY, 2011, 22 (06) : 517 - 522
  • [35] Road to remission: a comprehensive review of therapy in uveitis
    Siddique, Sana S.
    Shah, Rajiv
    Suelves, Ana M.
    Foster, Charles Stephen
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (11) : 1497 - 1515
  • [36] Biologic therapy for uveitis
    Hemmati, Houman D.
    Dunn, James P.
    EXPERT REVIEW OF OPHTHALMOLOGY, 2010, 5 (02) : 225 - 239
  • [37] Pharmacotherapy for uveitis: current management and emerging therapy
    Barry, Robert J.
    Quan Dong Nguyen
    Lee, Richard W.
    Murray, Philip I.
    Denniston, Alastair K.
    CLINICAL OPHTHALMOLOGY, 2014, 8 : 1891 - 1911
  • [38] Systematic review of clinical practice guidelines for uveitis
    Ghadiri, Nima
    Reekie, Ian R.
    Gordon, Iris
    Safi, Sare
    Lingham, Gareth
    Evans, Jennifer R.
    Keel, Stuart
    BMJ OPEN OPHTHALMOLOGY, 2023, 8 (01):
  • [39] Demographic and Clinical Features of Pediatric Uveitis in Israel
    Habot-Wilner, Zohar
    Tiosano, Liran
    Sanchez, Juan M.
    Shulman, Shiri
    Barequet, Dana
    Rahat, Ori
    Amarilyo, Gil
    Amer, Radgonde
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2020, 28 (01) : 43 - 53
  • [40] Juvenile Uveitis
    Eidherr, Markus
    Jarz-Lackner, Hildrun
    Bolz, Matthias
    Barisani-Asenbauer, Talin
    Strauss, Rupert W.
    SPEKTRUM DER AUGENHEILKUNDE, 2024, 38 (05) : 191 - 208